Institution
World Health Organization
Government•Islamabad, Pakistan•
About: World Health Organization is a government organization based out in Islamabad, Pakistan. It is known for research contribution in the topics: Population & Public health. The organization has 13330 authors who have published 22232 publications receiving 1322023 citations. The organization is also known as: World Health Organisation & WHO.
Topics: Population, Public health, Health care, Health policy, Global health
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A meta‐analysis of population‐based studies of breast cancer and reproductive variables in the Nordic countries confirmed that low parity and late age at first birth are significant and independent determinants of breast‐cancer risk, and suggested that several individual Nordic studies may have had too little power to detect the weak effect of age atFirst birth observed in the meta-analysis.
Abstract: Several large epidemiological studies in the Nordic countries have failed to confirm an association between age at first birth and breast cancer independent of parity. To assess whether lack of power or heterogeneity between the countries could explain this, a meta-analysis was performed of 8 population-based studies (3 cohort and 5 case-control) of breast cancer and reproductive variables in the Nordic countries, including a total of 5,568 cases. It confirmed that low parity and late age at first birth are significant and independent determinants of breast-cancer risk. Nulliparity was assoclated with a 30% increase in risk compared with parous women, and for every 2 births, the risk was reduced by about 16%. There was a significant trend of increasing risk with increasing age at first birth, women giving first birth after the age of 35 years having a 40% increased risk compared to those with a first birth before the age of 20 years. Tests for heterogeneity between studies were not significant for any of the examined variables. In the absence of bias, this suggests that several individual Nordic studies may have had too little power to detect the weak effect of age at first birth observed in the meta-analysis.
291 citations
••
TL;DR: The article provides an overview of ICF taxonomy, introduces the conceptual model which underpins ICF and elaborates on how ICF is used at population and clinical level.
Abstract: A common framework for describing functional status information is needed in order to make this information comparable and of value. The World Health Organization’s International Classification of Functioning, Disability and Health (ICF), which has been approved by all its member states, provides this common language and framework. The article provides an overview of ICF taxonomy, introduces the conceptual model which underpins ICF and elaborates on how ICF is used at population and clinical level. Furthermore, the article presents key features of the ICF tooling environment and outlines current and future developments of the classification.
291 citations
••
TL;DR: The GPELF has earlier been described as a ‘best buy’ in global health; this present tally of attributable health benefits from its first 8 years strengthens this notion considerably.
Abstract: Background
In its first 8 years, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) achieved an unprecedentedly rapid scale-up: >1.9 billion treatments with anti-filarial drugs (albendazole, ivermectin, and diethylcarbamazine) were provided via yearly mass drug administration (MDA) to a minimum of 570 million individuals living in 48 of the 83 initially identified LF-endemic countries.
291 citations
••
TL;DR: American tIypanosomiasis is more widespread as an enzootic disease than as a human infection, and the better living conditions of the population and the sylvatic characteristics of the local species of triatomines make human infection by the vector extremely rare.
290 citations
••
TL;DR: Dihydroartemisinin-piperaquine is another effective first-line treatment for P. falciparum malaria and ACTs with long half-lives may provide some benefit, while the performance of the non-ACT (amodiaquine plus sulfadoxine-pyrimethamine) falls below WHO recommendations for first- line therapy in parts of Africa.
Abstract: Background
The World Health Organization recommends uncomplicated P. falciparum malaria is treated using Artemisinin-based Combination Therapy (ACT). This review aims to assist the decision making of malaria control programmes by providing an overview of the relative benefits and harms of the available options. Objectives To compare the effects of ACTs with other available ACT and non-ACT combinations for treating uncomplicated P. falciparum malaria.
Search strategy
We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE; EMBASE; LILACS, and the metaRegister of Controlled Trials (mRCT) to March 2009.
Selection criteria
Randomized head to head trials of ACTs in uncomplicated P. falciparum malaria. This review is limited to: dihydroartemisinin-piperaquine; artesunate plus mefloquine; artemether-lumefantrine (six doses); artesunate plus amodiaquine; artesunate plus sulfadoxine-pyrimethamine and amodiaquine plus sulfadoxine-pyrimethamine.
Data collection and analysis
Two authors independently assessed trials for eligibility and risk of bias, and extracted data. We analysed primary outcomes in line with the WHO 'Protocol for assessing and monitoring antimalarial drug efficacy' and compared drugs using risk ratios (RR) and 95% confidence intervals (CI). Secondary outcomes were effects on P. vivax, gametocytes, haemoglobin, and adverse events.
Main results
Fifty studiesmet the inclusion criteria. All five ACTs achieved PCR adjusted failure rates of <10%, in line with WHO recommendations, at most study sites. Dihydroartemisinin-piperaquine performed well compared to the ACTs in current use (PCR adjusted treatment failure versus artesunate plus mefloquine in Asia; RR 0.39, 95% CI 0.19 to 0.79; three trials, 1062 participants; versus artemether-lumefantrine in Africa; RR 0.39, 95% CI 0.24 to 0.64; three trials, 1136 participants). ACTs were superior to amodiaquine plus sulfadoxine-pyrimethamine in East Africa (PCR adjusted treatment failure versus artemether-lumefantrine; RR 0.12, 95% CI 0.06 to 0.24; two trials, 618 participants; versus AS+AQ; RR 0.44, 95% CI 0.22 to 0.89; three trials, 1515 participants). Dihydroartemisinin-piperaquine (RR 0.32, 95% CI 0.24 to 0.43; four trials, 1442 participants) and artesunate plus mefloquine (RR 0.30, 95% CI 0.21 to 0.41; four trials, 1003 participants) were more effective than artemether-lumefantrine at reducing the incidence of P. vivax over 42 days follow up.
Authors' conclusions
Dihydroartemisinin-piperaquine is another effective first-line treatment for P. falciparum malaria. The performance of the non-ACT (amodiaquine plus sulfadoxine-pyrimethamine) falls below WHO recommendations for first-line therapy in parts of Africa. In areas where primaquine is not being used for radical cure of P. vivax, ACTs with long half-lives may provide some benefit.
290 citations
Authors
Showing all 13385 results
Name | H-index | Papers | Citations |
---|---|---|---|
Christopher J L Murray | 209 | 754 | 310329 |
Michael Marmot | 193 | 1147 | 170338 |
Didier Raoult | 173 | 3267 | 153016 |
Alan D. Lopez | 172 | 863 | 259291 |
Zulfiqar A Bhutta | 165 | 1231 | 169329 |
Simon I. Hay | 165 | 557 | 153307 |
Robert G. Webster | 158 | 843 | 90776 |
Ali H. Mokdad | 156 | 634 | 160599 |
Matthias Egger | 152 | 901 | 184176 |
Paolo Boffetta | 148 | 1455 | 93876 |
Jean Bousquet | 145 | 1288 | 96769 |
Igor Rudan | 142 | 658 | 103659 |
Holger J. Schünemann | 141 | 810 | 113169 |
Richard M. Myers | 134 | 496 | 137791 |
Majid Ezzati | 133 | 443 | 137171 |